$バイオノミックス(BNOX.US)$BNC210 demonstrated a statistically significant improvement in post-traumatic stress disorder (PTSD) symptom severity with a clinically meaningful effect size suggesting a potential advantage over approved medications. BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments. Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's...
$バイオノミックス(BNOX.US)$Bionomics Reports Results of the Full Dataset Analysis from ATTUNE Phase 2b Trial of BNC210 in Patients with Post-Traumatic Stress Disorder 5 MINUTES AGO, 6:00 AM EDT VIA GLOBENEWSWIRE
$バイオノミックス(BNOX.US)$The Company has no outstanding debt, convertible securities, or warrants. Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad. Future Anticipated Milestones for BNC210 Clinical Program Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD. The Company plans to discuss a potential dose-ranging late-stage study of BNC210 in PTSD with the FDA; an update on the next st...
バイオノミックスに関するコメント
And the RULE for the win again!
Gap up rule in effect!
Mark the dates
BNC210's emerging safety and tolerability profile continues to support its differentiation over approved, available, and experimental psychoactive treatments.
Bionomics will meet with the U.S. Food & Drug Administration (FDA) to discuss BNC210's...
News
5 MINUTES AGO, 6:00 AM EDT
VIA GLOBENEWSWIRE
Back to watching closely list!
Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad.
Future Anticipated Milestones for BNC210 Clinical Program
Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.
The Company plans to discuss a potential dose-ranging late-stage study of BNC210 in PTSD with the FDA; an update on the next st...
Nov12 watch list for potential long rides multi-days 🔑
まだコメントはありません